LIVIVO - Search results -

Search results

Result 1 - 10 of total 37

Search options

Article ; Online: Taking a HIF pill for old age diseases?

Kaluz, Stefan / Tan, Chalet / Van Meir, Erwin G

Aging

2018 Volume 10, Issue 3, Page(s) 290–292

MeSH term(s)	Aging/physiology ; Animals ; Cardiovascular Diseases/metabolism ; Cardiovascular Diseases/prevention & control ; Gene Expression Regulation/drug effects ; Humans ; Hypoxia-Inducible Factor 1/administration & dosage ; Hypoxia-Inducible Factor 1/metabolism ; Hypoxia-Inducible Factor 1/pharmacology ; Neoplasms/metabolism ; Neoplasms/prevention & control ; Osteoarthritis/metabolism ; Osteoarthritis/prevention & control ; Osteoporosis/metabolism ; Osteoporosis/prevention & control ; Oxygen/metabolism ; Oxygen Consumption ; Retinal Diseases/metabolism ; Retinal Diseases/prevention & control
Chemical Substances	Hypoxia-Inducible Factor 1 ; Oxygen (S88TT14065)
Language	English
Publishing date	2018-03-02
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ISSN	1945-4589
ISSN (online)	1945-4589
DOI	10.18632/aging.101395
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: A new species of Neoribates (Neoribates) (Acari: Oribatida: Parakalummidae) with key to the Neotropical species of the subgenus

Ermilov, Sergey G / Friedrich, Stefan / Kalúz, Stanislav

Biologia. 2016 July 14, v. 71, no. 6

2016

Abstract: A new species of oribatid mites of the subgenus Neoribates (Neoribates) (Oribatida: Parakalummidae), Neoribates (Neoribates) peruensis Ermilov sp. n., is described from soil and leaf litter in forests of Peru and Ecuador. This species differs from N. ( ... ...

Abstract	A new species of oribatid mites of the subgenus Neoribates (Neoribates) (Oribatida: Parakalummidae), Neoribates (Neoribates) peruensis Ermilov sp. n., is described from soil and leaf litter in forests of Peru and Ecuador. This species differs from N. (Neoribates) fulvusSellnick, 1923 by the smaller body size and the presence of prodorsal longitudinal ridge and straight anterior margin of notogaster. An identification key to the Neotropical species of Neoribates (Neoribates) is presented.
Keywords	Acari ; Sarcoptiformes ; body size ; forests ; new species ; plant litter ; taxonomic keys ; tropics ; Ecuador ; Peru
Language	English
Dates of publication	2016-0714
Size	p. 673-677.
Publishing place	De Gruyter
Document type	Article
ZDB-ID	419136-5
ISSN	1336-9563 ; 0006-3088 ; 1335-6372 ; 1335-6380
ISSN (online)	1336-9563
ISSN	0006-3088 ; 1335-6372 ; 1335-6380
DOI	10.1515/biolog-2016-0079
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Cologne/Königswinter

Zs.B 791: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Correction: EZH2 targeting reduces medulloblastoma growth through epigenetic reactivation of the BAI1/p53 tumor suppressor pathway.

Zhang, Hanwen / Zhu, Dan / Zhang, Zhaobin / Kaluz, Stefan / Yu, Bing / Devi, Narra S / Olson, Jeffrey J / Van Meir, Erwin G

Oncogene

2019 Volume 39, Issue 5, Page(s) 1165

Abstract: An amendment to this paper has been published and can be accessed via a link at the top of the paper. ...

Abstract	An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Language	English
Publishing date	2019-11-02
Publishing country	England
Document type	Published Erratum
ZDB-ID	639046-8
ISSN	1476-5594 ; 0950-9232
ISSN (online)	1476-5594
ISSN	0950-9232
DOI	10.1038/s41388-019-1067-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2218: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Targeting HIF-activated collagen prolyl 4-hydroxylase expression disrupts collagen deposition and blocks primary and metastatic uveal melanoma growth.

Kaluz, Stefan / Zhang, Qing / Kuranaga, Yuki / Yang, Hua / Osuka, Satoru / Bhattacharya, Debanjan / Devi, Narra S / Mun, Jiyoung / Wang, Wei / Zhang, Ruiwen / Goodman, Mark M / Grossniklaus, Hans E / Van Meir, Erwin G

Oncogene

2021 Volume 40, Issue 33, Page(s) 5182–5191

Abstract: Uveal melanoma (UM) is the most prevalent primary intraocular malignancy in adults, and patients that develop metastases (~50%) survive <1 year, highlighting the urgent need for new therapies. TCGA has recently revealed that a hypoxia gene signature is ... ...

Abstract	Uveal melanoma (UM) is the most prevalent primary intraocular malignancy in adults, and patients that develop metastases (~50%) survive <1 year, highlighting the urgent need for new therapies. TCGA has recently revealed that a hypoxia gene signature is associated with poor UM patient prognosis. Here we show that expression of hypoxia-regulated collagen prolyl-4-hydroxylase genes P4HA1 and P4HA2 is significantly upregulated in UM patients with metastatic disease and correlates with poor prognosis, suggesting these enzymes might be key tumor drivers. We targeted hypoxia-induced expression of P4HA1/2 in UM with KCN1, a hypoxia inducible factor-1 (HIF-1) pathway inhibitor and found potent inhibition of primary and metastatic disease and extension of animal survival, without overt side effects. At the molecular level, KCN1 antagonized hypoxia-induced expression of P4HA1 and P4HA2, which regulate collagen maturation and deposition in the extracellular matrix. The treatment decreased prolyl hydroxylation, induced proteolytic cleavage and rendered a disordered structure to collagen VI, the main collagen produced by UM, and reduced UM cell invasion. Together, these data demonstrate that extracellular collagen matrix formation can be targeted in UM by inhibiting hypoxia-induced P4HA1 and P4HA2 expression, warranting further development of this strategy in patients with uveal melanoma.
MeSH term(s)	Extracellular Matrix ; Humans ; Hydroxylation ; Hypoxia-Inducible Factor-Proline Dioxygenases ; Melanoma ; Transcriptional Activation ; Up-Regulation ; Uveal Neoplasms
Chemical Substances	Hypoxia-Inducible Factor-Proline Dioxygenases (EC 1.14.11.29)
Language	English
Publishing date	2021-07-03
Publishing country	England
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	639046-8
ISSN	1476-5594 ; 0950-9232
ISSN (online)	1476-5594
ISSN	0950-9232
DOI	10.1038/s41388-021-01919-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2218: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: EZH2 targeting reduces medulloblastoma growth through epigenetic reactivation of the BAI1/p53 tumor suppressor pathway.

Zhang, Hanwen / Zhu, Dan / Zhang, Zhaobin / Kaluz, Stefan / Yu, Bing / Devi, Narra S / Olson, Jeffrey J / Van Meir, Erwin G

Oncogene

2019 Volume 39, Issue 5, Page(s) 1041–1048

Abstract: Medulloblastoma (MB) is a malignant pediatric brain tumor for which new therapies are urgently needed. We demonstrate that treatment with EPZ-6438 (Tazemetostat), an enhancer of zeste homolog 2 (EZH2) inhibitor approved for clinical trials, blocks MB ... ...

Abstract	Medulloblastoma (MB) is a malignant pediatric brain tumor for which new therapies are urgently needed. We demonstrate that treatment with EPZ-6438 (Tazemetostat), an enhancer of zeste homolog 2 (EZH2) inhibitor approved for clinical trials, blocks MB cell growth in vitro and in vivo, and prolongs survival in orthotopic xenograft models. We show that the therapeutic effect is dependent on epigenetic reactivation of adhesion G-protein-coupled receptor B1 (BAI1/ADGRB1), a tumor suppressor that controls p53 stability by blocking Mdm2. Histone 3 trimethylated on lysine 27 (H3K27me3), a marker of silent chromatin conformation is present at the ADGRB1 promoter, and inhibition of EZH2, the catalytic component of the Polycomb Repressive complex 2 (PRC2) that methylates H3K27, switches the gene into an active chromatin status and reactivates BAI1 expression. Mechanistically, targeting EZH2 promotes transition from H3K27me3 to H3K27ac at the promoter, recruits the C/EBPβ (CREB-binding protein) and CBP transcription factors and activates ADGRB1 gene transcription. Taken together, our results identify key molecular players that regulate ADGRB1 gene expression in MB, demonstrate that reactivation of BAI1 expression underlies EPZ-6438 antitumorigenic action, and provide preclinical proof-of-principle evidence for targeting EZH2 in patients with MB.
MeSH term(s)	Angiogenic Proteins/deficiency ; Angiogenic Proteins/genetics ; CCAAT-Enhancer-Binding Protein-beta/metabolism ; Cell Line, Tumor ; Cell Proliferation/genetics ; Cell Transformation, Neoplastic ; Enhancer of Zeste Homolog 2 Protein/metabolism ; Epigenesis, Genetic ; Gene Silencing ; Histones/metabolism ; Humans ; Medulloblastoma/pathology ; Methylation ; Peptide Fragments/metabolism ; Receptors, G-Protein-Coupled/deficiency ; Receptors, G-Protein-Coupled/genetics ; Sialoglycoproteins/metabolism ; Tumor Suppressor Protein p53/genetics
Chemical Substances	ADGRB1 protein, human ; Angiogenic Proteins ; CCAAT-Enhancer-Binding Protein-beta ; Histones ; Peptide Fragments ; Receptors, G-Protein-Coupled ; Sialoglycoproteins ; Tumor Suppressor Protein p53 ; bone sialoprotein (35-62), human ; EZH2 protein, human (EC 2.1.1.43) ; Enhancer of Zeste Homolog 2 Protein (EC 2.1.1.43)
Language	English
Publishing date	2019-10-03
Publishing country	England
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	639046-8
ISSN	1476-5594 ; 0950-9232
ISSN (online)	1476-5594
ISSN	0950-9232
DOI	10.1038/s41388-019-1036-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2218: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Purifying Properly Folded Cysteine-rich, Zinc Finger Containing Recombinant Proteins for Structural Drug Targeting Studies: the CH1 Domain of p300 as a Case Example.

Kim, Yong Joon / Kaluz, Stefan / Mehta, Anil / Weinert, Emily / Rivera, Shannon / Van Meir, Erwin G

Bio-protocol

2017 Volume 7, Issue 17

Abstract: The transcription factor Hypoxia-Inducible Factor (HIF) complexes with the coactivator p300, activating the hypoxia response pathway and allowing tumors to grow. The CH1 and CAD domains of each respective protein form the interface between p300 and HIF. ... ...

Abstract	The transcription factor Hypoxia-Inducible Factor (HIF) complexes with the coactivator p300, activating the hypoxia response pathway and allowing tumors to grow. The CH1 and CAD domains of each respective protein form the interface between p300 and HIF. Small molecule compounds are in development that target and inhibit HIF/p300 complex formation, with the goal of reducing tumor growth. High resolution NMR spectroscopy is necessary to study ligand interaction with p300-CH1, and purifying high quantities of properly folded p300-CH1 is needed for pursuing structural and biophysical studies. p300-CH1 has 3 zinc fingers and 9 cysteine residues, posing challenges associated with reagent compatibility and protein oxidation. A protocol has been developed to overcome such issues by incorporating zinc during expression and streamlining the purification time, resulting in a high yield of optimally folded protein (120 mg per 4 L expression media) that is suitable for structural NMR studies. The structural integrity of the final recombinant p300-CH1 has been verified to be optimal using onedimensional
Language	English
Publishing date	2017-09-29
Publishing country	United States
Document type	Journal Article
ZDB-ID	2833269-6
ISSN	2331-8325
ISSN	2331-8325
DOI	10.21769/BioProtoc.2537
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: A novel small-molecule arylsulfonamide causes energetic stress and suppresses breast and lung tumor growth and metastasis.

Dai, Xin / Kaluz, Stefan / Jiang, Ying / Shi, Lei / Mckinley, DeAngelo / Wang, Yingzhe / Wang, Binghe / Van Meir, Erwin G / Tan, Chalet

Oncotarget

2017 Volume 8, Issue 59, Page(s) 99245–99260

Abstract: Neoplastic cells display reprogrammed metabolism due to the heightened energetic demands and the need for biomass synthesis of a growing tumor. Targeting metabolic vulnerabilities is thus an important goal for cancer therapy. Here, we describe a novel ... ...

Abstract	Neoplastic cells display reprogrammed metabolism due to the heightened energetic demands and the need for biomass synthesis of a growing tumor. Targeting metabolic vulnerabilities is thus an important goal for cancer therapy. Here, we describe a novel small-molecule arylsulfonamide (N-cyclobutyl-N-((2,2-dimethyl-2
Language	English
Publishing date	2017-11-21
Publishing country	United States
Document type	Journal Article
ZDB-ID	2560162-3
ISSN	1949-2553 ; 1949-2553
ISSN (online)	1949-2553
ISSN	1949-2553
DOI	10.18632/oncotarget.22104
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: At the crossroads of cancer and inflammation: Ras rewires an HIF-driven IL-1 autocrine loop.

Kaluz, Stefan / Van Meir, Erwin G

Journal of molecular medicine (Berlin, Germany)

2010 Volume 89, Issue 2, Page(s) 91–94

MeSH term(s)	Gene Expression Regulation, Neoplastic ; Glioblastoma/physiopathology ; Humans ; Hypoxia-Inducible Factor 1, alpha Subunit/genetics ; Hypoxia-Inducible Factor 1, alpha Subunit/metabolism ; Interleukin-1beta/metabolism ; Proto-Oncogene Proteins p21(ras)/metabolism
Chemical Substances	Hypoxia-Inducible Factor 1, alpha Subunit ; Interleukin-1beta ; Proto-Oncogene Proteins p21(ras) (EC 3.6.5.2)
Language	English
Publishing date	2010-12-15
Publishing country	Germany
Document type	Journal Article ; Comment
ZDB-ID	1223802-8
ISSN	1432-1440 ; 0946-2716
ISSN (online)	1432-1440
ISSN	0946-2716
DOI	10.1007/s00109-010-0706-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.36: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Design and synthesis of benzopyran-based inhibitors of the hypoxia-inducible factor-1 pathway with improved water solubility.

Ferguson, Jalisa H / De Los Santos, Zeus / Devi, Saroja N / Kaluz, Stefan / Van Meir, Erwin G / Zingales, Sarah K / Wang, Binghe

Journal of enzyme inhibition and medicinal chemistry

2017 Volume 32, Issue 1, Page(s) 992–1001

Abstract: While progress has been made in treating cancer, cytotoxic chemotherapeutic agents are still the most widely used drugs and are associated with severe side-effects. Drugs that target unique molecular signalling pathways are needed for treating cancer ... ...

Abstract	While progress has been made in treating cancer, cytotoxic chemotherapeutic agents are still the most widely used drugs and are associated with severe side-effects. Drugs that target unique molecular signalling pathways are needed for treating cancer with low or no intrinsic toxicity to normal cells. Our goal is to target hypoxic tumours and specifically the hypoxia inducible factor (HIF) pathway for the development of new cancer therapies. To this end, we have previously developed benzopyran-based HIF-1 inhibitors such as arylsulfonamide KCN1. However, KCN1 and its earlier analogs have poor water solubility, which hamper their applications. Herein, we describe a series of KCN1 analogs that incorporate a morpholine moiety at various positions. We found that replacing the benzopyran group of KCN1 with a phenyl group with a morpholinomethyl moiety at the para positions had minimal effect on potency and improved the water solubility of two new compounds by more than 10-fold compared to KCN1, the lead compound.
MeSH term(s)	Benzopyrans/chemical synthesis ; Benzopyrans/chemistry ; Benzopyrans/pharmacology ; Drug Design ; Hypoxia-Inducible Factor 1/antagonists & inhibitors ; Solubility ; Water/chemistry
Chemical Substances	Benzopyrans ; Hypoxia-Inducible Factor 1 ; Water (059QF0KO0R)
Language	English
Publishing date	2017-08-01
Publishing country	England
Document type	Journal Article
ZDB-ID	2082578-X
ISSN	1475-6374 ; 1475-6366
ISSN (online)	1475-6374
ISSN	1475-6366
DOI	10.1080/14756366.2017.1347784
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3004: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Comment on the role of FIH in the inhibitory effect of bortezomib on hypoxia-inducible factor-1.

Kaluz, Stefan / Kaluzová, Milota / Stanbridge, Eric J

Blood

2008 Volume 111, Issue 10, Page(s) 5258–9; author reply 5259–61

MeSH term(s)	Boronic Acids/pharmacology ; Bortezomib ; Cell Line ; Humans ; Hypoxia-Inducible Factor 1/drug effects ; Mixed Function Oxygenases ; Pyrazines/pharmacology ; Repressor Proteins/physiology ; Transcription Factors/physiology
Chemical Substances	Boronic Acids ; Hypoxia-Inducible Factor 1 ; Pyrazines ; Repressor Proteins ; Transcription Factors ; Bortezomib (69G8BD63PP) ; Mixed Function Oxygenases (EC 1.-) ; HIF1AN protein, human (EC 1.14.11.-)
Language	English
Publishing date	2008-05-08
Publishing country	United States
Document type	Comment ; Letter
ZDB-ID	80069-7
ISSN	1528-0020 ; 0006-4971
ISSN (online)	1528-0020
ISSN	0006-4971
DOI	10.1182/blood-2008-02-140079
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.140: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 364: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito